Paper Details

  1. Home
  2. Paper Details

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Author: BargetziMario, BiemondBart J, BoeckxNancy, BrooimansRik A, ChalandonYves, DrägerAngelika M, GratamaJan W, GrauxCarlos, HessUrs, HuijgensPeter C, Jongen-LavrecicMojca, KelderAngèle, KuballJurgen, LegdeurMarie-Cecile, LöwenbergBob, MaertensJohan, OssenkoppeleGert J, OussorenYvonne J M, PabstThomas, PasswegJakob R, PreijersFrank W M B, SchanzUrs, ScholtenWillemijn J, SchuurhuisGerrit J, SlompJennita, SnelAlexander N, TerwijnMonique, ValkPeter J M, VekemansMarie-Christiane, VerdonckLeo F, WijermansPierre, de GreefGeorgine E, de WeerdtOkke, van GelderMichel, van PuttenWim L J, van der VeldenVincent H J

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

About half of people with acute myeloid leukemia (AML) who achieve remission eventually relapse. This study aims to assess the usefulness of a test called minimal residual disease (MRD) for identifying AML patients who are at higher risk of relapse. This study focuses on using a specific type of MRD test that looks at the immune system's response to leukemia cells, and will be conducted in a large clinical trial with data collected from multiple centers.
Paper Details　
Original Abstract of the Article :
Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered responsible for the outgrowth of AML. In many retrospective studies, detection of minimal residual disease (MRD) has been shown to enable i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2012.45.9628

データ提供：米国国立医学図書館（NLM）

Unveiling the Hidden Enemy in Acute Myeloid Leukemia: The Power of Minimal Residual Disease Detection

In the [battle against acute myeloid leukemia (AML)], the persistent threat of [relapse] remains a formidable foe. This study, conducted within the framework of the [HOVON/SAKK AML 42A study], investigates the [prognostic significance] of [flow cytometric minimal residual disease (MRD) detection] in identifying patients at high risk of relapse. The authors demonstrate the [independent prognostic impact] of MRD detection, highlighting its ability to identify patients who may benefit from more aggressive treatment strategies. The study emphasizes the importance of [multi-center clinical trials] in validating the clinical utility of MRD detection in AML management.

The Hidden Enemy Revealed: MRD Detection and AML Relapse

This study sheds light on the critical role of MRD detection in predicting relapse in AML. The findings suggest that patients with detectable MRD face a significantly higher risk of relapse, emphasizing the need for [early intervention] and [personalized treatment plans]. The study's findings underscore the crucial role of [multi-center collaboration] in advancing our understanding and management of AML.

Navigating the Landscape of AML: The Power of Early Detection

As a traveler through the complex desert of hematological diseases, I find this study particularly insightful. The ability to identify patients at high risk of AML relapse through MRD detection empowers us to personalize treatment and potentially improve outcomes. This study underscores the importance of early detection and the transformative power of collaboration in conquering this formidable foe.

Dr. Camel's Conclusion

In the battle against AML, the early detection of minimal residual disease is a crucial weapon. This study highlights the importance of MRD detection in predicting relapse and informing personalized treatment strategies. It's a testament to the power of scientific collaboration in uncovering the hidden pathways to improved outcomes in this challenging disease.

Date :
  1. Date Completed 2013-12-31
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

24062400

DOI: Digital Object Identifier

10.1200/JCO.2012.45.9628

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.